DSNKY
Daiichi Sankyo Company, Limited
OTC Markets OTCPKUSDEQUITY
DELAYED
Sell
-35/100
Last price
17.45
▲ 0.08 (0.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
17.37
Day high
17.52
Day low
17.38
Volume
5.89K
Market cap
—
P/E (TTM)
—
52W range
14.98 – 27.50
Trailing performance
Returnvs SPY
1W
-3.00%
-5.0%
1M
-3.11%
-4.3%
3M
+4.18%
-0.3%
6M
-4.07%
-22.3%
YTD
-17.84%
-32.1%
1Y
-30.89%
-47.3%
3Y
-36.15%
-118.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on DSNKY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.12T | $1.89T | $1.60T | $1.28T | +12.6% |
| Operating revenue | $2.12T | $1.89T | $1.60T | $1.28T | +12.6% |
| Cost of revenue | $669.04B | $415.80B | $415.32B | $363.52B | +60.9% |
| Gross profit | $1.45T | $1.47T | $1.19T | $914.95B | -1.1% |
| Research & development | $466.00B | $435.96B | $365.17B | $341.57B | +6.9% |
| Selling, general & admin | $780.68B | $731.20B | $637.00B | $471.22B | +6.8% |
| Total operating expense | $1.22T | $1.14T | $974.78B | $794.37B | +7.6% |
| Operating income | $229.09B | $331.93B | $211.59B | $120.58B | -31.0% |
| Net interest income | $32.83B | $22.25B | $25.46B | $6.29B | +47.6% |
| Pre-tax income | $263.43B | $355.63B | $237.23B | $126.85B | -25.9% |
| Tax provision | $3.56B | $59.87B | $36.22B | $17.67B | -94.1% |
| Net income | $259.87B | $295.76B | $200.73B | $109.19B | -12.1% |
| Net income to common | $259.87B | $295.76B | $200.73B | $109.19B | -12.1% |
| Basic EPS | 140.44 | 155.96 | 104.69 | 56.95 | -10.0% |
| Diluted EPS | 140.37 | 155.87 | 104.62 | 56.91 | -9.9% |
| EBIT | $271.42B | $367.49B | $243.26B | $135.33B | -26.1% |
| EBITDA | $348.88B | $436.13B | $302.91B | $203.12B | -20.0% |
| Basic shares | 1.85B | 1.90B | 1.92B | 1.92B | -2.4% |
| Diluted shares | 1.85B | 1.90B | 1.92B | 1.92B | -2.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $449.81B | $639.84B | $647.18B | $441.92B | -29.7% |
| Cash & short-term investments | $554.54B | $720.73B | $1.22T | $825.13B | -23.1% |
| Inventory | $692.38B | $514.91B | $438.11B | $301.61B | +34.5% |
| Total current assets | $2.14T | $1.91T | $2.17T | $1.50T | +12.2% |
| Property, plant & equipment | $596.56B | $498.52B | $421.69B | $348.91B | +19.7% |
| Goodwill & intangibles | $338.42B | $344.27B | $276.80B | $257.94B | -1.7% |
| Total assets | $4.01T | $3.46T | $3.46T | $2.51T | +15.9% |
| Total current liabilities | $885.02B | $754.03B | $723.40B | $530.26B | +17.4% |
| Current debt | $404.00M | $399.00M | $399.00M | $41.40B | +1.3% |
| Long-term debt | $300.08B | $100.93B | $101.31B | $101.69B | +197.3% |
| Total debt | $300.48B | $101.33B | $101.71B | $143.09B | +196.5% |
| Total liabilities | $2.34T | $1.83T | $1.77T | $1.06T | +27.7% |
| Retained earnings | $1.55T | $1.46T | $1.39T | $1.23T | +6.4% |
| Shareholder equity | $1.66T | $1.62T | $1.69T | $1.45T | +2.5% |
| Working capital | $1.26T | $1.16T | $1.45T | $964.79B | +8.8% |
| Net tangible assets | $1.33T | $1.28T | $1.41T | $1.19T | +3.6% |
| Shares issued | 1.89B | 1.91B | 1.95B | 1.95B | -0.7% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $263.43B | $355.63B | $237.23B | $126.85B | -25.9% |
| Depreciation & amortisation | $77.46B | $68.65B | $59.65B | $67.79B | +12.8% |
| Change in working capital | -$55.78B | -$186.44B | $337.31B | -$7.38B | +70.1% |
| Operating cash flow | $77.66B | $53.84B | $599.26B | $114.51B | +44.2% |
| Capital expenditure | -$149.00B | -$187.87B | -$122.79B | -$67.37B | +20.7% |
| Investing cash flow | -$148.24B | $334.17B | -$282.64B | -$257.78B | -144.4% |
| Dividends paid | -$128.43B | -$114.32B | -$67.08B | -$54.62B | -12.3% |
| Financing cash flow | -$97.88B | -$377.77B | -$123.56B | -$89.59B | +74.1% |
| Free cash flow | -$71.35B | -$134.03B | $476.47B | $47.15B | +46.8% |
| End cash position | $488.98B | $639.84B | $647.18B | $441.92B | -23.6% |
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Basic EPS | 37.72 | — | — | — |
| Diluted EPS | 37.70 | — | — | — |
| Basic shares | 1.82B | 1.85B | 1.86B | -1.7% |
| Diluted shares | 1.82B | 1.85B | 1.86B | -1.6% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $449.81B | $542.16B | $639.84B | -17.0% |
| Cash & short-term investments | $554.54B | $593.59B | $720.73B | -6.6% |
| Accounts receivable | $741.14B | $616.85B | $619.10B | +20.1% |
| Inventory | $692.38B | $608.55B | $514.91B | +13.8% |
| Total current assets | $2.14T | $1.88T | $1.91T | +14.2% |
| Property, plant & equipment | $596.56B | $551.30B | $498.52B | +8.2% |
| Goodwill & intangibles | $338.42B | $344.12B | $344.27B | -1.7% |
| Total assets | $4.01T | $3.57T | $3.46T | +12.2% |
| Total current liabilities | $885.02B | $856.06B | $754.03B | +3.4% |
| Current debt | $404.00M | $100.40B | $399.00M | -99.6% |
| Long-term debt | $300.08B | $100.74B | $100.93B | +197.9% |
| Total debt | $300.48B | $201.14B | $101.33B | +49.4% |
| Total liabilities | $2.34T | $1.92T | $1.83T | +22.2% |
| Retained earnings | $1.55T | $1.49T | $1.46T | +4.2% |
| Shareholder equity | $1.66T | $1.65T | $1.62T | +0.7% |
| Working capital | $1.26T | $1.02T | $1.16T | +23.2% |
| Net tangible assets | $1.33T | $1.31T | $1.28T | +1.3% |
| Shares issued | 1.89B | 1.89B | 1.91B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.93
-2.66% from price
SMA 20
18.15
-3.85% from price
SMA 50
17.81
-2.03% from price
SMA 100
17.12
+1.95% from price
SMA 200
18.03
-3.23% from price
EMA 12
17.86
-2.28% from price
EMA 26
17.97
-2.87% from price
EMA 50
17.80
-1.96% from price
RSI (14)
41.8
Neutral
MACD (12,26,9)
-0.11
Hist -0.17
ATR (14)
0.66
3.77% of price
Realised vol 30D
26.1%
Annualised
Bollinger upper
19.30
20, 2σ
Bollinger lower
16.99
20, 2σ
50 / 200 cross
Death
17.81 vs 18.03
Trend bias
Below 200
-3.23%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.78
Less volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
26.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.8%
Peak to trough
Max drawdown 5Y
-64.1%
Peak to trough
ATR 14
0.66
3.77% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Zacks · 2d ago
Will there be more to Daiichi’s story than DXd ADCs?
Pharma Voice · 2d ago
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
Simply Wall St. · 5d ago
Sector Update: Healthcare Stocks Steady Late Afternoon
MT Newswires · 5d ago
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
GuruFocus.com · 5d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 5d ago
Sector Update: Healthcare
MT Newswires · 5d ago
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Pharmaceutical Technology · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.